• Product nameAnti-PSAP antibody [PASE/4LJ]
    See all PSAP primary antibodies
  • Description
    Mouse monoclonal [PASE/4LJ] to PSAP
  • SpecificityThis antibody does not inhibit the enzymatic activity of PSAP. It reacts with non-neoplastic adult and fetal prostatic glands, primary and metastatic prostatic carcinomas. It shows no cross reaction with other phosphatases.
  • Tested applicationsSuitable for: IHC-P, ICC/IF, Flow Cytmore details
  • Species reactivity
    Reacts with: Human
    Does not react with: Rat, Rabbit, Dog
  • Immunogen

    Purified PSAP from Human seminal plasma.

  • Positive control
    • Normal prostate or prostate carcinoma.



Our Abpromise guarantee covers the use of ab80717 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/1500.
ICC/IF Use at an assay dependent concentration.
Flow Cyt Use 0.1µg for 106 cells. ab170190-Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.


  • FunctionThe lysosomal degradation of sphingolipids takes place by the sequential action of specific hydrolases. Some of these enzymes require specific low-molecular mass, non-enzymic proteins: the sphingolipids activator proteins (coproteins).
    Saposin-A and saposin-C stimulate the hydrolysis of glucosylceramide by beta-glucosylceramidase (EC and galactosylceramide by beta-galactosylceramidase (EC Saposin-C apparently acts by combining with the enzyme and acidic lipid to form an activated complex, rather than by solubilizing the substrate.
    Saposin-B stimulates the hydrolysis of galacto-cerebroside sulfate by arylsulfatase A (EC, GM1 gangliosides by beta-galactosidase (EC and globotriaosylceramide by alpha-galactosidase A (EC Saposin-B forms a solubilizing complex with the substrates of the sphingolipid hydrolases.
    Saposin-D is a specific sphingomyelin phosphodiesterase activator (EC
  • Involvement in diseaseDefects in PSAP are the cause of combined saposin deficiency (CSAPD) [MIM:611721]; also known as prosaposin deficiency. CSAPD is due to absence of all saposins, leading to a fatal storage disorder with hepatosplenomegaly and severe neurological involvement.
    Defects in PSAP saposin-B region are the cause of leukodystrophy metachromatic due to saposin-B deficiency (MLD-SAPB) [MIM:249900]. MLD-SAPB is an atypical form of metachromatic leukodystrophy. It is characterized by tissue accumulation of cerebroside-3-sulfate, demyelination, periventricular white matter abnormalities, peripheral neuropathy. Additional neurological features include dysarthria, ataxic gait, psychomotr regression, seizures, cognitive decline and spastic quadriparesis.
    Defects in PSAP saposin-C region are the cause of atypical Gaucher disease (AGD) [MIM:610539]. Affected individuals have marked glucosylceramide accumulation in the spleen without having a deficiency of glucosylceramide-beta glucosidase characteristic of classic Gaucher disease, a lysosomal storage disorder.
    Defects in PSAP saposin-A region are the cause of atypical Krabbe disease (AKRD) [MIM:611722]. AKRD is a disorder of galactosylceramide metabolism. AKRD features include progressive encephalopathy and abnormal myelination in the cerebral white matter resembling Krabbe disease.
    Note=Defects in PSAP saposin-D region are found in a variant of Tay-Sachs disease (GM2-gangliosidosis).
  • Sequence similaritiesContains 2 saposin A-type domains.
    Contains 4 saposin B-type domains.
  • Post-translational
    This precursor is proteolytically processed to 4 small peptides, which are similar to each other and are sphingolipid hydrolase activator proteins.
    N-linked glycans show a high degree of microheterogeneity.
    The one residue extended Saposin-B-Val is only found in 5% of the chains.
  • Cellular localizationLysosome.
  • Information by UniProt
  • Database links
  • Alternative names
    • A1 activator antibody
    • Cerebroside sulfate activator antibody
    • Co-beta-glucosidase antibody
    • Component C antibody
    • CSAct antibody
    • Dispersin antibody
    • GLBA antibody
    • Glucosylceramidase activator antibody
    • Proactivator polypeptide antibody
    • Proactivator polypeptide precursor antibody
    • Prosaposin (sphingolipid activator protein 1) antibody
    • prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy) antibody
    • Prosaposin antibody
    • Protein A antibody
    • Protein C antibody
    • PSAP antibody
    • SAP-1 antibody
    • SAP-2 antibody
    • SAP_HUMAN antibody
    • SAP1 antibody
    • Saposin A antibody
    • Saposin B antibody
    • Saposin B Val antibody
    • Saposin C antibody
    • Saposin D antibody
    • Saposin-D antibody
    • Saposins antibody
    • Sgp1 antibody
    • Sphingolipid activator protein 1 antibody
    • Sphingolipid activator protein 2 antibody
    • Sulfated glycoprotein 1 antibody
    • Sulfatide/GM1 activator antibody
    see all

Anti-PSAP antibody [PASE/4LJ] images

  • Overlay histogram showing HepG2 cells stained with ab80717 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab80717, 0.1μg/1x106 cells) for 30 min at 22°C. The secondary antibody used was Alexa Fluor® 488 goat anti-mouse IgG (H+L) (ab150113) at 1/2000 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter.
  • Formalin-fixed, paraffin-embedded human prostate stained with ab80717 at a 1/1500 dilution using alkaline phosphatase-conjugate and fast red chromogen. Note intense cytoplasmic staining of glandular epithelial cells.

References for Anti-PSAP antibody [PASE/4LJ] (ab80717)

This product has been referenced in:
  • Haines AM  et al. A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer 60:887-92 (1989). ICC/IF, IHC-P ; Human . Read more (PubMed: 2605098) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab80717.
Please use the links above to contact us or submit feedback about this product.